Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy

JAMA

Volumn 276, Issue 2, 1996, Pages 118-125

  Katlama, Christine ^a   Ingrand, Didier ^a   Loveday, Clive ^b   Clumeck, Nathan ^c   Mallolas, Jose ^d   Staszewski, Schlomo ^e   Johnson, Margaret ^f   Hill, Andrew M ^g   Pearce, Gill ^g   McDade, Hugh ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 8944225025     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.2.118     Document Type: Article

References (42)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191.
2. Sande MA, Carpenter CCJ, Cobbs CG, et al. Antiviral therapy for adult HIV-infected patients: recommendations from a state of the art conference. JAMA. 1993;270:2583-2589.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;332:941-949.
4. Concorde Co-ordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection. Lancet. 1994;348:871-881.
5. Kahn JD, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992;327:581-587.
6. Yeni P, on behalf of the International Coordinating Committee. Preliminary results of the European/Australian DELTA trial: based on data up to 31 May 1995. In: Program and abstracts of the 5th European Conference on Clinical Aspects and Treatment of HIV Infection; September 26-29, 1995; Copenhagen, Denmark.
7. Hammer SD, Katzenstein D, Hughes M, et al, for the ACTG 176 Study Team. Nucleoside monotherapy (MT) vs combination therapy (CT) in HIV infected adults: a randomised double blind placebo controlled trial in persons with CD4 counts between 200 and 500. In: Program and abstracts of the 5th European Conference on Clinical Aspects and Treatment of HIV Infection; September 26-29, 1995; Copenhagen, Denmark.
8. Sommadossi JP, Schinazi RF, Cu CK et al. Comparison of cytotoxicity of the (-) and (+) enantiomer of 2′, 3′-deoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol. 1992;44:1921-1925.
9. Cui L, Yoon S, Schinazi RF, et al. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest. 1995; 95:555-563.
10. Hart GJ, Orr DC, Penn C, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus transcriptase and mammalian DNA polymerases alpha, beta, gamma. Antimicrob Agents Chemother. 1992;36:1688-1694.
11. Van Leeuwen R, Katlama C, Kitchen V, et al. The safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic HIV-1 infection: a phase I/II study. J Infect Dis. 1995;171:1166-1171.
12. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995;171:1438-1447.
13. Viner KC, Cammack N, Coates JAV, et al. (-) Enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in combination with AZT synergistically inhibits clinical isolates of HIV-1. In: Program and abstracts of the IX International Conference on AIDS; June 7-11, 1993; Berlin, Germany. Abstract PO A25 0607.
14. Rana KZ, Horton CM, Yuen GJ, et al. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-infected individuals. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract A62:83.
15. Semple M, Loveday C, Weller I, Tedder R. HIV plasma viraemia quantification: a non-culture measurement needed for therapeutic trials. J Virol Methods. 1993;41:167-180.
16. Mulder J, McKineey N, Christopherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
17. Kaye S, Loveday C, Tedder R. A microtiter format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients with zidovudine. J Med Virol. 1992;37:241-246.
18. Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
19. Table for Grading of Adult Adverse Experiences. Washington, DC: National Institute of Allergy and Infectious Diseases, Division of AIDS; August 1992.
20. Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst. 1960;37:351-361.
21. 2 tests. Biometrics. 1954;10:417-451.
22. Dawson JD. Comparing treatment groups on the basis of slopes, areas under-the-curve, and other summary measures. Drug Info J. 1994;28:723-732.
23. Larder BA, Kemp SD, Harrigan PR. Potential mechanisms for sustained antiretroviral potency of AZT/3TC combination therapy. Science. 1995;269: 696-699.
24. Rubin M. New drug application for lamivudine (Epivir™). Presented at the FDA Division of Antiviral Drug Products and Antiviral Drugs Advisory Committee Meeting; November 6, 1995; Washington, DC.
25. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
26. Fischl MA, Richmann DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double blind, placebo-controlled trial. Ann Intern Med. 1990;112:727-737.
27. Follansbee S, Drew L, Olson R, et al. The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (AZT) as monotherapy in patients with advanced HIV disease: a randomised double blind controlled trial (ACTG114). In: Program and abstracts of the 9th International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract NOPO-B26-2113.
28. Dolin R, Amato D, Fischl M, et al. Efficacy of didanosine (ddI) versus zidovudine (AZT) in patients with no or <16 weeks of prior zidovudine therapy. In: Program and abstracts of the 9th International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract WS-B24-1.
29. Vella S, Florida M, Tomino C, et al. Comparative evaluations of zidovudine and ddI in AIDS patients with previous zidovudine treatment. In: Program and abstracts of the X Conference on AIDS; August 7-12, 1994; Yokohama, Japan. Abstract B0271.
30. + cell counts less than 300: preliminary results. In: Program and abstracts of the 4th European Conference on Clinical Aspects and Treatment of HIV; March 16-18, 1994; Milan, Italy. Abstract 052.
31. + lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
32. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
33. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426-431.
34. Jackson B. Clinical correlates of viral and immunological measurements in zidovudine naive or experienced subjects who received zidovudine or didanosine therapy (ACTG 116a/116b/117). In: Program and abstracts of the Second National Conference on Human Retroviruses and Related Infections; January 29-February 2, 1995; Washington, DC.
35. Shafer R, Kozal M, Winters M, et al. Combination therapy with zidovudine + ddI suppresses virus load but does not prevent the emergence of HIV-1 isolates with zidovudine resistance. In: Program and abstracts of the 9th International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract WS-B25-3.
36. Gu Z, Gao Q, Li X, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transeriptase gene that encodes cross-resistance to 2′ ,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol. 1992;66:7128-7135.
37. Gao Q, Gu Z, Parnick MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′ ,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1993; 37:1390-1392.
38. Schuurman R, Nijhuis M, Van Leeuwen R, et al. Changes in HIV-1 RNA load and appearance of drug resistance mutations in individuals treated with 3TC (lamivudine). J Infect Dis. 1995;171:1411-1419.
39. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1995;39:1624-1628.
40. Wainberg MA, Zhengxian GU. Targeting HIV reverse transcriptase in novel ways. Nat Med. 1995; 1:628-629.
41. Wainberg MA, Drosopoulos WC, Salomon H, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 1996;271:1282-1285.
42. Pandey VN, Kaushik N, Rege N, et al. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry. 1996;35:2168-2179.